A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Asthma

NCT07015749 | Recruiting Phase 1

• 1 other identifier: CIBI3002T001
• Study Type: interventional
• Target: 12
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of IBI3002 multiple doses in participants with asthma. The study plans to enroll participants with asthma on stable inhaled treatment, FeNO≥25ppb at screening and randomization, elevated peripheral blood eosinophils and Pre-BD FEV1 ≤ 80% of the prediction. The safety, tolerability, PK, immunogenicity and changes in PD and clinical characteristics of multiple doses of IBI3002 in asthma subjects will be evaluated. The entire study includes the screening period (4 weeks before dosing), the treatment period (12 weeks), and the safety follow-up period (8 weeks). The study plans to enroll 9 to 27 participants with asthma, who will be randomly assigned in a 1:1:1 ratio to the following 3 cohorts to receive subcutaneous injection of the corresponding dose of IBI3002 or a matching volume of placebo. Investigators and participants will remain blind within the cohort. Cohort 1: 150mg SC(IBI3002: placebo =2 :1); Cohort 2: 300mg SC(IBI3002: placebo =2 :1); Cohort 3: 600mg SC(IBI3002: placebo =2 :1); The participants need to be observed at the study site for 3 hours after each dose and are allowed to leave after investigators determine no safety risk.

Conditions

Asthma

Outcome Measures

Primary Outcomes (1)

• To evaluate the safety and tolerability of multiple doses of IBI3002 in participants with asthma

  The incidence of Adverse events (AE) and Serious Adverse events (SAE) in participants with asthma after multiple administrations of IBI3002;

  Baseline to Week 20

Secondary Outcomes (4)

• To evaluate the pharmacokinetic (PK) parameters of IBI3002 in participants with asthma

  Baseline to Week 20

• To evaluate the pharmacokinetic (PK) parameters of IBI3002 in participants with asthma

  Baseline to Week 20

• To evaluate the pharmacokinetic (PK) parameters of IBI3002 in participants with asthma

  Baseline to Week 20

• To evaluate the pharmacokinetic (PK) parameters of IBI3002 in participants with asthma

  Baseline to Week 20

Study Arms (6)

IBI3002 600mg SC

EXPERIMENTAL

Participants with asthma will receive IBI3002 600mg SC

Drug: IBI3002

IBI3002 150mg SC

EXPERIMENTAL

Participants with asthma will receive IBI3002 150mg SC

Drug: IBI3002

Placebo 4ml SC

PLACEBO COMPARATOR

Participants with asthma will receive Placebo 4ml SC

Drug: Placebo

Placebo 1ml SC

PLACEBO COMPARATOR

Participants with asthma will receive Placebo 1ml SC

Drug: Placebo

Placebo 2ml SC

PLACEBO COMPARATOR

Participants with asthma will receive Placebo 2ml SC

Drug: Placebo

IBI3002 300mg SC

EXPERIMENTAL

Participants with asthma will receive IBI3002 300mg SC

Drug: IBI3002

Interventions

Placebo DRUG

Participants with asthma will receive Placebo at the corresponding dose and dosing interval.

Placebo 1ml SC; Placebo 2ml SC; Placebo 4ml SC

IBI3002 DRUG

Participants with asthma will receive IBI3002 at the corresponding dose and dosing interval.

IBI3002 150mg SC; IBI3002 300mg SC; IBI3002 600mg SC

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged between 18 and 65 years old (inclusive).
• Weight ≥40kg.
• Diagnosed with Asthma for ≥12 months in accordance with the Global Initiative for Asthma (GINA) and confirmed by the Investigator.
• Receiving inhaled treatment with or without inhaled corticosteroids (ICS), which has been stablized for ≥ 1 month and confirmed by the Investigator.
• FeNO ≥25ppb at screening and randomization.
• Elevated peripheral blood eosinophils, defined as ≥300/μL in within 6 months prior to screening; OR ≥150/μL at screening.
• Pre-bronchodilator forced expiratory volume in 1 second (pre-BD FEV) ≤ 80% of prediction.

You may not qualify if:

• Co-exsiting diseases that may have an impact on the participant's own safety or participation in the study, in the opinion of the Investigator. Including but not limited to mental disorders, diseases of the central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, blood system or metabolic system.
• A known history of active tuberculosis or clinically suspected manifestations of tuberculosis (including but not limited to pulmonary tuberculosis, lymph node tuberculosis, tuberculous pleurisy, etc.); Or chest imaging suggests the existence of suspected evidence of tuberculosis. Those with positive T-SPOT.TB need to receive preventive anti-tuberculosis treatment from 4 weeks before the first administration until the end of the study.
• The peripheral blood white blood cells or neutrophils are lower than the lower limit of the normal value at screening or randomization.
• Experience of life-threatening asthma attacks requiring mechanical ventilation and/or asthma attacks related to hypercapnia, respiratory failure or hypoxic epilepsy within the 5 years prior to randomization.
• History of other lung diseases besides asthma, including but not limited to chronic obstructive pulmonary disease, interstitial lung disease, etc, in the opinion of the Investigator.
• The above information is not intended to contain all considerations relevant to a participant's potential participation in this trial.

Sponsors & Collaborators

• The First Affiliated Hospital of Soochow University: lead
• Innovent Biologics (Suzhou) Co. Ltd.: collaborator

Study Sites (1)

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, 215000, China

RECRUITING

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial Diseases; Respiratory Tract Diseases; Lung Diseases, Obstructive; Lung Diseases; Respiratory Hypersensitivity; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Central Study Contacts

Wensheng Zang

CONTACT

15210342569; wensheng.zang@innoventbio.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 4, 2025
• First Posted: June 11, 2025
• Study Start: June 20, 2025
• Primary Completion (Estimated): May 20, 2026
• Study Completion (Estimated): May 20, 2026
• Last Updated: November 19, 2025

Record last verified: 2025-11

Locations

CN (1)